PatchSight-ImmuneMap-LifeSpan as a unified AI framework for breast cancer diagnosis, immune profiling and prognostic prediction.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: The framework reports specific breast-cancer diagnosis, TIL-detection and survival-prediction evaluations on public datasets, qualifying as task-specific retrospective validation. No prospective clinical validation or new biology is shown, and reported performance varies by dataset/task.
Technology: Methods/Results evaluate InceptionResNetV2 on BreakHis, Faster R-CNN on LYSTO and survival prediction on public datasets; test metrics include survival C-index around 0.74. These are benchmark-dataset task evaluations, not deployment evidence.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Methods/Results evaluate InceptionResNetV2 on BreakHis, Faster R-CNN on LYSTO and survival prediction on public datasets; test metrics include survival C-index around 0.74. These are benchmark-dataset task evaluations, not deployment evidence.
- Limitation / still unknown
- Evaluations use public retrospective datasets; performance varies by diagnostic, immune-profiling and survival task, with no prospective clinical validation or new biological finding reported.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://link.springer.com/article/10.1007/s12672-026-04491-6
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.